Drug Trial Radar · NCT04728516
The Effect of Dual Eradication Therapy vs PPI on Gastrointestinal Bleeding in ACS Patients
Last checked: Nov 19, 2026Latest source record: Sep 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
2,600
Planned (sponsor's estimate)
Start
Apr 12, 2023
Primary completion
Jun 30, 2026
Study completion Jun 30, 2026
Sponsor
- Lead sponsor
- Qilu Hospital of Shandong UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 28, 2021
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Patients with acute coronary syndrome (ACS) after Percutaneous Coronary Intervention (PCI) require routine treatment with dual antiplatelet (DAPT) treatment, but with the high risk of bleeding, gastrointestinal bleeding is the most common type of major bleeding. Helicobacter pylori (Hp) infection is a high-risk factor for gastrointestinal bleeding, with an incidence of about 50%. Foreign authoritative DAPT guidelines do not give individual guidance to Hp-infected patients. It is recommended that those with high bleeding risk should be combined with proton pump inhibitors (PPI), but long-term compliance with PPI is not ideal. Authoritative experts in China have agreed to recommend Hp detection and eradication therapy for DAPT patients, but loss of evidence. Vonoprazan is a novel potassium ion competitive acid blocker, based on Vonoprazan's dual Hp eradication therapy is simple and effective. Our team will conduct a multi-center, open-label, randomized controlled clinical trial using a non-inferior design to compare the combination of Vonoprazan + amoxicillin combined with pantoprazole (PPI) for 6 months after PCI on the bleeding events of the digestive tract.
Conditions
- Acute Coronary Syndrome
- Helicobacter Pylori Infection
Interventions
Vonoprazan-based dual eradication therapy for two weeksDrug
Patients with ACS after PCI, associated with positive Hp need a long-term DAPT treatment. We conducted a study on the prevention of gastrointestinal bleeding between vonoprazan-based dual eradication therapy for two weeks and pantoprazole for six months of a rountine therapy.
amoxicillinDrug
amoxicillin
PantoprazoleDrug
Pantoprazole
Primary outcomes
What the sponsor says the trial is designed to measure.
- Gastrointestinal bleeding of 6 months in patients with ACS after PCITime frame: 6 months
Locations
42 sites in 1 country. Site status is shown where the registry gives one.
Bozhou People's Hospital
Bozhou, Anhui, China · Recruiting
Chuzhou First People's Hospital
Chuzhou, Anhui, China · Recruiting
The First Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China · Not yet recruiting
Aviation General Hospital
Beijing, Beijing Municipality, China · Recruiting
China-Japan Friendship Hospital
Beijing, Beijing Municipality, China · Recruiting
The First People'S Hospital of Zunyi
Zunyi, Guizhou, China · Recruiting
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China · Recruiting
The First Affiliated Hospital of Dalian Medical University
Dalian, Liaoning, China · Recruiting
Qinghai Red Cross Hospital
Xining, Qinghai, China · Recruiting
Qilu Hospital of Shandong University Dezhou Hospital
Dezhou, Shandong, China · Recruiting
Pingyuan First People'S Hospital
Dezhou, Shandong, China · Recruiting
NINGJIN People's Hospital
Dezhou, Shandong, China · Recruiting
Dongying People's Hospital
Dongying, Shandong, China · Recruiting
THE Second People's Hospital of Dongying
Dongying, Shandong, China · Recruiting
Heze Municipal Hospital
Heze, Shandong, China · Recruiting
The 960th Hospital of the Joint Logistic Support Force
Jinan, Shandong, China · Withdrawn
Shandong Second Provincial General Hospital
Jinan, Shandong, China · Withdrawn
Affiliated Hospital of Shandong University of Traditional Chinese Medicine
Jinan, Shandong, China · Recruiting
Qilu Hospital of Shandong University
Jinan, Shandong, China · Not yet recruiting
Shandong Provincial Third Hospital
Jinan, Shandong, China · Recruiting
The fourth People's Hospital of jinan
Jinan, Shandong, China · Recruiting
Shandong Public Health Clinical Center
Jinan, Shandong, China · Recruiting
JINA CITY People's Hospital
Jinan, Shandong, China · Recruiting
Central Hospital Affiliated to Shandong First medical University
Jinan, Shandong, China · Withdrawn
The First People's Hospital of Jining City
Jining, Shandong, China · Not yet recruiting
Liaocheng People's Hospital
Liaocheng, Shandong, China · Not yet recruiting
Linyi City People's Hospital
Linyi, Shandong, China · Not yet recruiting
Linshu County People'S Hospital
Linyi, Shandong, China · Recruiting
Qilu Hospital of Shandong University (Qingdao)
Qingdao, Shandong, China · Not yet recruiting
The Affiliated Hospital of Qingdao University
Qingdao, Shandong, China · Recruiting
Affiliated Hospital of Shandong Second Medical University
Weifang, Shandong, China · Recruiting
Weifang Hospital of Traditional Chinese Medicine
Weifang, Shandong, China · Recruiting
Weihai Central Hospital
Weihai, Shandong, China · Withdrawn
Weihai Municipal Hospital
Weihai, Shandong, China · Not yet recruiting
Haiyang People's Hospital
Yantai, Shandong, China · Recruiting
Shandong Healthcare Group Zaozhuang Central Hospital
Zaozhuang, Shandong, China · Withdrawn
Zaozhuang Municipal Hospital
Zaozhuang, Shandong, China · Recruiting
Zibo Central Hospital
Zibo, Shandong, China · Withdrawn
The Ninth People's Hospital Affiliated to Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, China · Not yet recruiting
Hospital of Chengdu University of Traditional Chinese Medicine
Chengdu, Sichuan, China · Withdrawn
Showing 40 of 42 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.